Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3)

被引：38

作者：

Yamani, Abdellah ^{[1
]}

Zdzalik-Bielecka, Daria ^{[2
,5
]}

Lipner, Joanna ^{[1
,6
]}

Stanczak, Aleksandra ^{[2
,3
]}

Piorkowska, Natalia ^{[1
]}

Stanczak, Paulina Seweryna ^{[2
,7
]}

Olejkowska, Patrycja ^{[1
]}

Hucz-Kalitowska, Joanna ^{[2
]}

Magdycz, Marta ^{[1
,6
]}

Dzwonek, Karolina ^{[2
]}

Dubiel, Krzysztof ^{[1
]}

Lamparska-Przybysz, Monika ^{[2
,4
]}

Popiel, Delfina ^{[2
]}

Pieczykolan, Jerzy ^{[2
]}

Wieczorek, Maciej ^{[2
,3
]}

机构：

[1] Celon Pharma SA, Med Chem Dept, Mokra 41A, PL-05092 Kielpin, Lomianki, Poland

[2] Celon Pharma SA, Preclin Dev Dept, Mokra 41A, PL-05092 Kielpin, Lomianki, Poland

[3] Celon Pharma SA, Clin Trials Dept, Ogrodowa 2A, PL-05092 Kielpin, Lomianki, Poland

[4] Polpharma, Bobrowiecka 6, PL-00728 Warsaw, Poland

[5] Int Inst Mol & Cell Biol, Lab Cell Biol, Warsaw, Poland

[6] Pikralida Sp Zoo, Bukowska 70, PL-60812 Poznan, Poland

[7] OncoArendi Therapeut, Zwirki & Wigury 101, Warsaw, Poland

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 210卷

关键词：

Anti-tumor activity; FGFR (1-3) inhibitor; Pyrazole-benzimidazole; TYROSINE KINASE INHIBITOR; BREAST-CANCER; MUTATIONS; FAMILY; JNJ-42756493; ERDAFITINIB; DERIVATIVES; ABERRATIONS; ACTIVATION; PROGNOSIS;

D O I：

10.1016/j.ejmech.2020.112990

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The FGFR family is characterized by four receptors (FGFR 1-4), binding to 18 ligands called fibroblast growth factors (FGFs). Aberrant activation of FGFs and their FGFRs has been implicated in a broad spectrum of human tumors. We employed the scaffolds hybridization approach, scaffold-hopping concept to synthesize a series of novel pyrazole-benzimidazole derivatives 56 (a-x). Compound 56q (CPL304110) was identified as a selective and potent pan-FGFR inhibitor for FGFR1, -2, -3 with IC(50)s of 0.75 nM, 0.50 nM, 3.05 nM respectively, whereas IC50 of 87.90 nM for FGFR4. Due to its favorable pharmacokinetic profile, low toxicity and potent anti-tumor activity in vivo, compound 56q is currently under evaluation in phase I clinical trial for the treatment of bladder, gastric and squamous cell lung cancers (01FGFR2018; NCT04149691). (C) 2020 Elsevier Masson SAS. All rights reserved.

引用

页数：31

共 56 条

[1] The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors [J].

Ancker, Ole Vincent ;

Wehland, Markus ;

Bauer, Johann ;

Infanger, Manfred ;

Grimm, Daniela .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (03)

[2] ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT [J].

BERNS, EMJJ ;

FOEKENS, JA ;

VANSTAVEREN, IL ;

VANPUTTEN, WLJ ;

DEKONING, HYWCM ;

PORTENGEN, H ;

KLIJN, JGM .

GENE, 1995, 159 (01) :11-18

[3] Imidazole and benzimidazole derivatives as chemotherapeutic agents [J].

Boiani, M ;

González, M .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (04) :409-424

[4] Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer [J].

Brooks, A. Nigel ;

Kilgour, Elaine ;

Smith, Paul D. .

CLINICAL CANCER RESEARCH, 2012, 18 (07) :1855-1862

[5] Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor [J].

Brown, AP ;

Courtney, CL ;

King, LM ;

Groom, SC ;

Graziano, MJ .

TOXICOLOGIC PATHOLOGY, 2005, 33 (04) :449-455

[6] Anti-inflammatory trends of new benzimidazole derivatives [J].

Bukhari, Syed Nasir Abbas ;

Lauro, Gianluigi ;

Jantan, Ibrahim ;

Chee, Chin Fei ;

Amjad, Muhammad Wahab ;

Bifulco, Giuseppe ;

Sher, Hassan ;

Abdullah, Iskandar ;

Abd Rahman, Noorsaadah .

FUTURE MEDICINAL CHEMISTRY, 2016, 8 (16) :1953-1967

[7] Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].

Chesi, M ;

Nardini, E ;

Brents, LA ;

Schrock, E ;

Ried, T ;

Kuehl, WM ;

Bergsagel, PL .

NATURE GENETICS, 1997, 16 (03) :260-264

[8] Bendamustine: Rebirth of an Old Drug [J].

Cheson, Bruce D. ;

Rummel, Mathias J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1492-1501

[9] Genomic and transcriptional aberrations linked to breast cancer pathophysiologies [J].

Chin, Koei ;

DeVries, Sandy ;

Fridlyand, Jane ;

Spellman, Paul T. ;

Roydasgupta, Ritu ;

Kuo, Wen-Lin ;

Lapuk, Anna ;

Neve, Richard M. ;

Qian, Zuwei ;

Ryder, Tom ;

Chen, Fanqing ;

Feiler, Heidi ;

Tokuyasu, Taku ;

Kingsley, Chris ;

Dairkee, Shanaz ;

Meng, Zhenhang ;

Chew, Karen ;

Pinkel, Daniel ;

Jain, Ajay ;

Ljung, Britt Marie ;

Esserman, Laura ;

Albertson, Donna G. ;

Waldman, Frederic M. ;

Gray, Joe W. .

CANCER CELL, 2006, 10 (06) :529-541

[10] Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives [J].

Dieci, Maria Vittoria ;

Arnedos, Monica ;

Andre, Fabrice ;

Soria, Jean Charles .

CANCER DISCOVERY, 2013, 3 (03) :264-279

← 1 2 3 4 5 6 →